<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277601</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-174-0149</org_study_id>
    <secondary_id>2010-024586-45</secondary_id>
    <nct_id>NCT01277601</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B</brief_title>
  <official_title>A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys®) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of tenofovir disoproxil
      fumarate (TDF) plus peginterferon α-2a (Peg-IFN) combination therapy for 48 weeks versus
      standard of care TDF monotherapy or Peg-IFN monotherapy for 48 weeks in non-cirrhotic adults
      with chronic hepatitis B virus (HBV) as determined by loss of hepatitis B surface antigen
      (HBsAg).

      The study will consist of 2 phases for participants in the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks
      + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups. Following an initial 48 weeks of treatment,
      participants in these groups will be monitored for 24 weeks for signs of worsening HBV, and
      those meeting TDF retreatment and flare management criteria will be eligible to receive TDF
      monotherapy during a retreatment phase, up to Week 120.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBsAg Loss at Weeks 96 and 120</measure>
    <time_frame>Baseline; Weeks 96 and 120</time_frame>
    <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120</measure>
    <time_frame>Baseline; Weeks 72, 96, and 120</time_frame>
    <description>HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBeAg Loss and Seroconversion at Week 72</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBeAg Loss and Seroconversion at Week 96</measure>
    <time_frame>Baseline; Week 96</time_frame>
    <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBeAg Loss and Seroconversion at Week 120</measure>
    <time_frame>Baseline; Week 120</time_frame>
    <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 120</measure>
    <time_frame>Week 120</time_frame>
    <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal ALT at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal ALT at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal ALT at Week 120</measure>
    <time_frame>Week 120</time_frame>
    <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required Retreatment</measure>
    <time_frame>Up to 120 weeks</time_frame>
    <description>Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">751</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF+Peg-IFN 48 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF plus Peg-IFN for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF 48 Weeks + Peg-IFN 16 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF 120 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF monotherapy for 120 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg-IFN 48 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peg-IFN monotherapy for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>TDF 300 mg tablets administered orally once daily</description>
    <arm_group_label>TDF+Peg-IFN 48 Weeks</arm_group_label>
    <arm_group_label>TDF 48 Weeks + Peg-IFN 16 Weeks</arm_group_label>
    <arm_group_label>TDF 120 Weeks</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN</intervention_name>
    <description>Peg-IFN 180 µg administered via subcutaneous injection once weekly</description>
    <arm_group_label>TDF+Peg-IFN 48 Weeks</arm_group_label>
    <arm_group_label>TDF 48 Weeks + Peg-IFN 16 Weeks</arm_group_label>
    <arm_group_label>Peg-IFN 48 Weeks</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (age 18-75) with chronic HBV (positive for serum hepatitis B surface antigen
             (HBsAg) or HBV DNA for at least 6 months) prior to baseline

          -  Anti-HBV treatment-naive adults; adults who have taken oral anti-HBV nucleoside
             therapy with the last dose ≥ 24 weeks prior to screening are also eligible.

          -  Positive or negative for hepatitis B e antigen (HBeAg)

          -  HBV DNA ≥ 20,000 IU/ml (HBeAg-positive participants) and ≥ 2,000 IU/ml (HBeAg-negative
             participants)

          -  Alanine aminotransferase (ALT) &gt; 54 U/L and ≤ 400 U/L for men and &gt; 36 U/L and ≤ 300
             U/L for women

          -  Creatinine clearance ≥ 70 mL/min

          -  Negative serum pregnancy test for females of childbearing potential

          -  Sexually active females of childbearing potential must agree to use a
             protocol-recommended method of contraception throughout the study and for 30 days
             following the last dose of study medication

          -  Lactating females must agree to discontinue nursing before initiation of study
             investigational medicinal product

        Exclusion Criteria:

          -  Known bridging fibrosis or cirrhosis and/or decompensated liver disease

          -  Evidence of hepatocellular carcinoma

          -  Significant kidney, heart, lung, neurological, autoimmune disease, or bone disease
             (eg, osteomalacia,chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis,
             multiple bone fractures)

          -  Absolute neutrophil count &lt; 1,500/mm^3, platelet &lt; 100,000/mm^3, hemoglobin &lt; 10 g/dL
             (female) or &lt; 11 g/dL (male)

          -  History of severe depression or severe psychiatric disease

          -  Thyroid dysfunction

          -  Coinfection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belinda Jump</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asian Pacific Liver Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Advanced Gastroenterology</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami / Jackson Memorial Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Gastroenterology/Center for Digestive Diseases</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Hospital and Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Care, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Procare, PLLC</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ. Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Liver Therapies at St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelsey Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas,</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia, Bon Secours Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire Research Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint George's Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital,Gastroenterology Department</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide SA</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincents Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Med Research Clinic, Univ of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Zeidler Ledcore Centre</name>
      <address>
        <city>Zeidler Ledcore Centre</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestional Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon &amp; Leslie Diamond Health Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver and Intestinal Research Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital,Division of Infectious Diseases</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon, Service Hepatologie- Centre Pierre Abrami</name>
      <address>
        <city>Clichy</city>
        <state>Cedex</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <state>Cedex</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire de Strasbourg, Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universitat Mainz,</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen - klinikum für Gastroenterolgie und Hepatologie,</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann-Wolfgang-Goethe Universitat,</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover,Hastroenterologie und Hepatologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Koln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ippokratio Hospital Salonica</name>
      <address>
        <city>Thessaloniki</city>
        <state>Attica</state>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ippokratio Hospital Athens</name>
      <address>
        <city>Attica</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Tai Po</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Hospital, Lakdi Ka Pul</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of digestive and liver disease, Dispur Hospital Ganeshguri</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vedanta Institute of Medical Sciences</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Clinic</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Hospitals</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hepatology, Institute of Liver Diseases, HPB Surgery and Transplant, Global Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seth GS Medical College and KEM Hospital, Acharya Donde Marg,Parel</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midas Institute of Gastroenterology</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dharamasi Hospital,Chandni Chowk, South Shivajinagar,</name>
      <address>
        <city>Sangli</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences, Ansari Nagar</name>
      <address>
        <city>Delhi</city>
        <state>New Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VGM Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Post Graduate Medical Education And Research</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Cagliari</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Universita degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Parma,Department of Infectious Diseases and hepatology</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV - Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan,Azienda Ospedaliera San Giovanni, Battista di Torino,Dipartimento di Gastroenterologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <state>Chungcheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Unversity Wonju College of Medicine Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-d</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-d</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggi-d</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Sungnam</city>
        <state>Gyeonggi-d</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsang</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsang</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsang</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang, Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Cntr, Konkuk Univ Hosp</name>
      <address>
        <city>Kwangjin-gu, Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Specjalistyczny Szpital im. Dr Wladyslawa Bieganskiego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny 1,Klinika Chorób Zakaznych,ulica Staszica 16</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Chorzowie</name>
      <address>
        <city>Chorzów</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny Kazimierza Dluskeigo w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Obserwacyjno Zakazny im. Tadeusza Browicza</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Specjalistyczny Szpital im. Dr Wladyslawa Bieganskiego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wojewodzki Szpital Zakazny</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Egas Moniz</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neomed Research</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase &quot;Prof. Dr. Matei Bals&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase Prof.Dr. Matei Bals</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si Tropicale &quot;Dr. Victor Babes&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Sibiu</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Particular Policlinic Algomed SRL-Gastroenterologie</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Meixoeiro</name>
      <address>
        <city>Vigo, Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far-Eastern Memorial Hosp</name>
      <address>
        <city>New Taipei City</city>
        <state>Banciao Dist</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation.LinKou Branch</name>
      <address>
        <city>Tao-Yuan</city>
        <state>Taoyuan</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christain Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiayi Christian Hosp</name>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaosiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Keelung</name>
      <address>
        <city>Keelung Town/KEELUNG CITY</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans Genl Hosp</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Üniversitesi Tip Fakültesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Üniversitesi Tip Fakültesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep Üniversitesi Tip Fakültesi, Sahinbey Arastirma ve Uygulama Hastanesi</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin Üniversitesi Tip Fakültesi, Saglik Arastirma ve Uygulama Hastanesi</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham, WSTMID</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead,London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and The London NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Study 149 Investigators. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. 2016 Jan;150(1):134-144.e10. doi: 10.1053/j.gastro.2015.09.043. Epub 2015 Oct 8.</citation>
    <PMID>26453773</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan HL, Elkhashab M, Trinh H, Tak WY, Ma X, Chuang WL, Kim YJ, Martins EB, Lin L, Dinh P, Charuworn P, Foster GR, Marcellin P. Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol. 2015 Nov;63(5):1086-92. doi: 10.1016/j.jhep.2015.06.025. Epub 2015 Jul 2.</citation>
    <PMID>26143444</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <results_first_submitted>August 10, 2015</results_first_submitted>
  <results_first_submitted_qc>August 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2015</results_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Hep B</keyword>
  <keyword>Non cirrhotic</keyword>
  <keyword>Tenofovir disoproxil fumarate (TDF)</keyword>
  <keyword>Peginterferon α-2a (Peg-IFN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in North America, Europe, Asia, and Australia. The first participant was screened on 12 April 2011. The last study visit occurred on 17 July 2015.</recruitment_details>
      <pre_assignment_details>1597 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TDF+Peg-IFN 48 Weeks</title>
          <description>Tenofovir disoproxil fumarate (TDF) 300 mg tablet once daily plus peginterferon α-2a (Peg-IFN) 180 µg subcutaneous (s.c.) injection once weekly for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>TDF 48 Weeks + Peg-IFN 16 Weeks</title>
          <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
        </group>
        <group group_id="P3">
          <title>TDF 120 Weeks</title>
          <description>TDF 300 mg tablet once daily for 120 weeks</description>
        </group>
        <group group_id="P4">
          <title>Peg-IFN 48 Weeks</title>
          <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="187"/>
                <participants group_id="P3" count="190"/>
                <participants group_id="P4" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Never Dosed with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Terminated from Study by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants were analyzed by actual treatment received.
11 participants were never dosed are not included in the Safety Analysis Set due to the following reasons for discontinuation: 7 = Subject Never Dosed with Study Drug; 4 = Withdrawal by Subject.</population>
      <group_list>
        <group group_id="B1">
          <title>TDF+Peg-IFN 48 Weeks</title>
          <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>TDF 48 Weeks + Peg-IFN 16 Week</title>
          <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
        </group>
        <group group_id="B3">
          <title>TDF 120 Weeks</title>
          <description>TDF 300 mg tablet once daily for 120 weeks</description>
        </group>
        <group group_id="B4">
          <title>Peg-IFN 48 Weeks</title>
          <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="186"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="185"/>
            <count group_id="B4" value="185"/>
            <count group_id="B5" value="740"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="10.7"/>
                    <measurement group_id="B2" value="37" spread="9.9"/>
                    <measurement group_id="B3" value="36" spread="10.8"/>
                    <measurement group_id="B4" value="38" spread="10.5"/>
                    <measurement group_id="B5" value="37" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="177"/>
                    <measurement group_id="B5" value="719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B Surface Antigen (HBsAg)</title>
          <units>log 10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.88" spread="0.840"/>
                    <measurement group_id="B2" value="3.84" spread="0.849"/>
                    <measurement group_id="B3" value="3.89" spread="0.812"/>
                    <measurement group_id="B4" value="3.76" spread="0.844"/>
                    <measurement group_id="B5" value="3.84" spread="0.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B e Antigen (HBeAg) Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Reactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonreactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B Virus (HBV) DNA</title>
          <units>log 10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.06" spread="1.542"/>
                    <measurement group_id="B2" value="7.13" spread="1.505"/>
                    <measurement group_id="B3" value="7.02" spread="1.550"/>
                    <measurement group_id="B4" value="6.94" spread="1.619"/>
                    <measurement group_id="B5" value="7.04" spread="1.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Genotype A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype E-H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.2" spread="180.82"/>
                    <measurement group_id="B2" value="112.2" spread="94.44"/>
                    <measurement group_id="B3" value="100.9" spread="67.65"/>
                    <measurement group_id="B4" value="106.6" spread="91.51"/>
                    <measurement group_id="B5" value="110.3" spread="116.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone</title>
        <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants in the TDF+Peg-IFN 48 Weeks, TDF 120 Weeks, and Peg-IFN 48 Weeks groups were analyzed by randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks</description>
          </group>
          <group group_id="O3">
            <title>Peg-IFN 48 Weeks</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone</title>
          <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants in the TDF+Peg-IFN 48 Weeks, TDF 120 Weeks, and Peg-IFN 48 Weeks groups were analyzed by randomized treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.05"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>Raw p-values comparing treatments were based on a log-rank test stratified by HBeAg status and viral genotype.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Raw p-values comparing treatments were based on a log-rank test stratified by HBeAg status and viral genotype.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone</title>
        <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Full Analysis Set. Participants in the TDF 48 week + Peg-IFN 16 Weeks, TDF 120 Weeks, and Peg-IFN 48 Weeks groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
          </group>
          <group group_id="O2">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks</description>
          </group>
          <group group_id="O3">
            <title>Peg-IFN 48 Weeks</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone</title>
          <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.</description>
          <population>Full Analysis Set. Participants in the TDF 48 week + Peg-IFN 16 Weeks, TDF 120 Weeks, and Peg-IFN 48 Weeks groups were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBsAg Loss at Weeks 96 and 120</title>
        <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.</description>
        <time_frame>Baseline; Weeks 96 and 120</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
          </group>
          <group group_id="O3">
            <title>TDF 120 Week</title>
            <description>TDF 300 mg tablet once daily for 120 weeks</description>
          </group>
          <group group_id="O4">
            <title>Peg-IFN 48 Weeks</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBsAg Loss at Weeks 96 and 120</title>
          <description>Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="185"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.69"/>
                    <measurement group_id="O2" value="3.49"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.36"/>
                    <measurement group_id="O2" value="3.49"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120</title>
        <description>HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.</description>
        <time_frame>Baseline; Weeks 72, 96, and 120</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
          </group>
          <group group_id="O3">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks</description>
          </group>
          <group group_id="O4">
            <title>Peg-IFN 48 Weeks</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120</title>
          <description>HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate.
The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="185"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05"/>
                    <measurement group_id="O2" value="0.56"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05"/>
                    <measurement group_id="O2" value="0.56"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.08"/>
                    <measurement group_id="O2" value="0.56"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBeAg Loss and Seroconversion at Week 72</title>
        <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg reactive or indeterminate at baseline were analyzed. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Week (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBeAg Loss and Seroconversion at Week 72</title>
          <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
          <population>Participants in the Full Analysis Set who were HBeAg reactive or indeterminate at baseline were analyzed. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="15.9"/>
                    <measurement group_id="O5" value="14.7"/>
                    <measurement group_id="O6" value="32.8"/>
                    <measurement group_id="O7" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="31.1"/>
                    <measurement group_id="O4" value="13.6"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="31.3"/>
                    <measurement group_id="O7" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBeAg Loss and Seroconversion at Week 96</title>
        <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
        <time_frame>Baseline; Week 96</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg reactive or indeterminate at baseline were analyzed. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Week (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBeAg Loss and Seroconversion at Week 96</title>
          <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
          <population>Participants in the Full Analysis Set who were HBeAg reactive or indeterminate at baseline were analyzed. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="45.5"/>
                    <measurement group_id="O4" value="14.8"/>
                    <measurement group_id="O5" value="18.3"/>
                    <measurement group_id="O6" value="37.8"/>
                    <measurement group_id="O7" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="43.2"/>
                    <measurement group_id="O4" value="13.1"/>
                    <measurement group_id="O5" value="16.5"/>
                    <measurement group_id="O6" value="29.7"/>
                    <measurement group_id="O7" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBeAg Loss and Seroconversion at Week 120</title>
        <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
        <time_frame>Baseline; Week 120</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg reactive or indeterminate at baseline were analyzed. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Week (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBeAg Loss and Seroconversion at Week 120</title>
          <description>Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit.
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
          <population>Participants in the Full Analysis Set who were HBeAg reactive or indeterminate at baseline were analyzed. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="37.5"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="20.2"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="21.9"/>
                    <measurement group_id="O3" value="35.0"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="15.6"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 72</title>
        <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
        <time_frame>Week 72</time_frame>
        <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 72</title>
          <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
          <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="185"/>
                <count group_id="O6" value="128"/>
                <count group_id="O7" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="15.1"/>
                    <measurement group_id="O5" value="84.9"/>
                    <measurement group_id="O6" value="11.7"/>
                    <measurement group_id="O7" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 96</title>
        <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
        <time_frame>Week 96</time_frame>
        <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 96</title>
          <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
          <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="185"/>
                <count group_id="O6" value="72"/>
                <count group_id="O7" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="68.0"/>
                    <measurement group_id="O3" value="15.7"/>
                    <measurement group_id="O4" value="80.2"/>
                    <measurement group_id="O5" value="83.8"/>
                    <measurement group_id="O6" value="13.9"/>
                    <measurement group_id="O7" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 120</title>
        <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
        <time_frame>Week 120</time_frame>
        <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 120</title>
          <description>For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
          <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="185"/>
                <count group_id="O6" value="68"/>
                <count group_id="O7" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="81.3"/>
                    <measurement group_id="O3" value="18.8"/>
                    <measurement group_id="O4" value="83.5"/>
                    <measurement group_id="O5" value="82.2"/>
                    <measurement group_id="O6" value="13.2"/>
                    <measurement group_id="O7" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal ALT at Week 72</title>
        <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
        <time_frame>Week 72</time_frame>
        <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Week (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal ALT at Week 72</title>
          <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 72, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 72.</description>
          <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="185"/>
                <count group_id="O6" value="120"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AASLD Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="18.3"/>
                    <measurement group_id="O3" value="40.7"/>
                    <measurement group_id="O4" value="18.2"/>
                    <measurement group_id="O5" value="47.6"/>
                    <measurement group_id="O6" value="35.0"/>
                    <measurement group_id="O7" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Laboratory Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="57.6"/>
                    <measurement group_id="O4" value="34.8"/>
                    <measurement group_id="O5" value="72.4"/>
                    <measurement group_id="O6" value="57.5"/>
                    <measurement group_id="O7" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal ALT at Week 96</title>
        <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
        <time_frame>Week 96</time_frame>
        <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Week (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal ALT at Week 96</title>
          <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 96, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 96.</description>
          <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="102"/>
                <count group_id="O5" value="185"/>
                <count group_id="O6" value="72"/>
                <count group_id="O7" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AASLD Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="34.1"/>
                    <measurement group_id="O4" value="46.1"/>
                    <measurement group_id="O5" value="48.1"/>
                    <measurement group_id="O6" value="34.7"/>
                    <measurement group_id="O7" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Laboratory Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="52.4"/>
                    <measurement group_id="O4" value="73.5"/>
                    <measurement group_id="O5" value="73.0"/>
                    <measurement group_id="O6" value="47.2"/>
                    <measurement group_id="O7" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal ALT at Week 120</title>
        <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
        <time_frame>Week 120</time_frame>
        <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O2">
            <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O3">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O4">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
          <group group_id="O5">
            <title>TDF 120 Weeks</title>
            <description>TDF 300 mg tablet once daily for 120 weeks. Participants in this group were not eligible to enter the retreatment phase.</description>
          </group>
          <group group_id="O6">
            <title>Peg-IFN 48 Week (Not Retreated)</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks in the initial treatment phase</description>
          </group>
          <group group_id="O7">
            <title>Peg-IFN 48 Weeks (Retreated)</title>
            <description>Following the randomized treatment, participants who met protocol-specified criteria were retreated with TDF 300 mg tablet once daily up to Week 120 in the retreatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal ALT at Week 120</title>
          <description>Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT).
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the &quot;Not Retreated&quot; column for participants who had not entered the retreatment phase by Week 120, and in the &quot;Retreated&quot; column for participants who did enter the retreatment phase by Week 120.</description>
          <population>Full Analysis Set. The missing = failure method was used in which participants on study with missing data were considered to have failed to achieve the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="185"/>
                <count group_id="O6" value="68"/>
                <count group_id="O7" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AASLD Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="30.4"/>
                    <measurement group_id="O4" value="48.7"/>
                    <measurement group_id="O5" value="48.6"/>
                    <measurement group_id="O6" value="30.9"/>
                    <measurement group_id="O7" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Laboratory Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="40.6"/>
                    <measurement group_id="O4" value="78.3"/>
                    <measurement group_id="O5" value="73.0"/>
                    <measurement group_id="O6" value="41.2"/>
                    <measurement group_id="O7" value="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required Retreatment</title>
        <description>Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.</description>
        <time_frame>Up to 120 weeks</time_frame>
        <population>Safety Analysis Set. Participants in the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF+Peg-IFN 48 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>TDF 48 Weeks + Peg-IFN 16 Weeks</title>
            <description>TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
          </group>
          <group group_id="O3">
            <title>Peg-IFN 48 Weeks</title>
            <description>Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required Retreatment</title>
          <description>Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.</description>
          <population>Safety Analysis Set. Participants in the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 120 weeks plus 30 days</time_frame>
      <desc>Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants were analyzed by actual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>TDF+Peg-IFN 48 Weeks (Not Retreated)</title>
          <description>Adverse events in this reporting group are those occurring in participants who were not retreated or before retreatment through last non-retreatment dose plus 30 days.
TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>TDF+Peg-IFN 48 Weeks (Retreated)</title>
          <description>Adverse events in this reporting group are those occurring after TDF retreatment through last TDF retreatment dose plus 30 days.
TDF 300 mg tablet once daily up to Week 120</description>
        </group>
        <group group_id="E3">
          <title>TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated)</title>
          <description>Adverse events in this reporting group are those occurring in participants who were not retreated or before retreatment through last non-retreatment dose plus 30 days.
TDF 300 mg tablet once daily plus Peg-IFN 180 µg s.c. injection once weekly for 16 weeks followed by TDF 300 mg tablet once daily for an additional 32 weeks</description>
        </group>
        <group group_id="E4">
          <title>TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)</title>
          <description>Adverse events in this reporting group are those occurring after TDF retreatment through last TDF retreatment dose plus 30 days.
TDF 300 mg tablet once daily up to Week 120</description>
        </group>
        <group group_id="E5">
          <title>TDF 120 Weeks</title>
          <description>Adverse events in this reporting group are those occurring during the initial treatment phase (up to 120 weeks plus 30 days).
TDF 300 mg tablet once daily for up to 120 weeks</description>
        </group>
        <group group_id="E6">
          <title>Peg-IFN 48 Weeks (Not Retreated)</title>
          <description>Adverse events in this reporting group are those occurring in participants who were not retreated or before retreatment through last non-retreatment dose plus 30 days.
Peg-IFN 180 µg s.c. injection once weekly for 48 weeks</description>
        </group>
        <group group_id="E7">
          <title>Peg-IFN 48 Weeks (Retreated)</title>
          <description>Adverse events in this reporting group are those occurring during the retreatment phase (from start of retreatment up to Week 120 plus 30 days).
TDF 300 mg tablet once daily up to Week 120</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cholesterosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gallbladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mixed hepatocellular cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="142" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="89" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="152" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

